ReviewEuropean endocrinology2018

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.

David H FitchettPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.